Psoriasis
7 competing products in clinical development for Psoriasis.
Pipeline by Phase
Phase 24
Phase 33
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 3 | Completed | 77 |
| 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo | Eli Lilly | Phase 3 | Completed | 77 |
| CT-P43 + Stelara | Celltrion | Phase 3 | Completed | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 2 | Completed | 52 |
| LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous | Eli Lilly | Phase 2 | Terminated | 52 |
| Placebo + Baricitinib | Eli Lilly | Phase 2 | Completed | 52 |
| VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo | Ventyx Biosciences | Phase 2 | Terminated | 47 |